Tumor Microenvironment and the Response to Anticancer Therapy
暂无分享,去创建一个
[1] B. Wouters,et al. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. , 2001, Cancer research.
[2] L. H. Gray,et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.
[3] M. Moses,et al. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. , 2001, Cancer research.
[4] P. Olive,et al. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. , 1989, British Journal of Cancer.
[5] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[6] J M Brown,et al. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. , 1979, The British journal of radiology.
[7] M. Lemmon,et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. , 1986, International journal of radiation oncology, biology, physics.
[8] B. Wouters,et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin , 1999, British Journal of Cancer.
[9] R. A. Malmgren,et al. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. , 1955, Cancer research.
[10] P. Lambin,et al. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. , 2001, FEMS immunology and medical microbiology.
[11] D. Gericke,et al. ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER. , 1964, Cancer research.
[12] M. Dewhirst,et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.
[13] J. Brown,et al. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. , 2000, Molecular medicine today.
[14] G. Semenza. Involvement of hypoxia-inducible factor 1 in human cancer. , 2002, Internal medicine.
[15] D. Dunlop,et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. E. Boxer,et al. ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS. , 1964, Cancer research.
[17] H. Lyng,et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis , 2000, British Journal of Cancer.
[18] W. Wilson,et al. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. , 1994, International journal of radiation oncology, biology, physics.
[19] B. Baguley,et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. , 1999, Cancer research.
[20] E. Neter,et al. Clostridial oncolysis in man , 1967 .
[21] J. Pouysségur,et al. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. , 2001, Trends in cell biology.
[22] P. V. Zijl,et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment , 1997, Gene Therapy.
[23] A. Giaccia,et al. Development of a hypoxia-responsive vector for tumor-specific gene therapy , 2000, Gene Therapy.
[24] D. Chaplin,et al. Acute hypoxia in tumors: implications for modifiers of radiation effects. , 1986, International journal of radiation oncology, biology, physics.
[25] J. Moese,et al. ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. , 1964, Cancer research.
[26] E. Rofstad. Microenvironment-induced cancer metastasis , 2000, International journal of radiation biology.
[27] I. Stratford,et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent , 2000, British Journal of Cancer.
[28] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[29] M. Dewhirst,et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] B Vojnovic,et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. , 1999, Cancer research.
[31] J. Raleigh,et al. Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.
[32] David E. Housman,et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.
[33] A. Harris,et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] M. Schindl,et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. , 2000, Cancer research.
[35] AQ4N: a new approach to hypoxia-activated cancer chemotherapy , 2000, British Journal of Cancer.
[36] R. Airley,et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours , 2002, Gene Therapy.
[37] R. Fisher,et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P. Glazer,et al. Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.
[39] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[40] M. Lemmon,et al. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. , 1990, Cancer research.
[41] J. Pawelek,et al. Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.
[42] L. H. Gray,et al. The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.
[43] P. Hoskin,et al. Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. , 1996, The British journal of cancer. Supplement.
[44] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[45] S. Spencer,et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. , 1998, International journal of radiation oncology, biology, physics.
[46] G. Semenza,et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.
[47] K. Kinzler,et al. Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[48] P H Watson,et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.
[49] A. Harris,et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. , 2001, Cancer research.
[50] J. Brown,et al. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. , 1989, Cancer research.
[51] M. Dorie,et al. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. , 1993, Cancer research.
[52] A. Koong,et al. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. , 1991, Journal of the National Cancer Institute.
[53] AJ Giaccia,et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis , 2002, Gene Therapy.
[54] Janice M. Y. Brown,et al. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.
[55] J. Overgaard,et al. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[56] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[57] G. Dachs,et al. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives , 2001, Journal of cellular physiology.
[58] A. Giaccia,et al. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. , 2002, Neoplasia.
[59] C. Lewis,et al. Expression of HIF‐1α by human macrophages: implications for the use of macrophages in hypoxia‐regulated cancer gene therapy , 2002, The Journal of pathology.
[60] R. Durand. The influence of microenvironmental factors during cancer therapy. , 1994, In vivo.
[61] W. Denny,et al. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia , 2000, Expert opinion on investigational drugs.
[62] John Mao,et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] D. Chaplin,et al. Intermittent blood flow in a murine tumor: radiobiological effects. , 1987, Cancer research.
[64] A. Harris,et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. , 2002, Cancer research.
[65] K. Peters,et al. Tirapazamine: a hypoxia-activated topoisomerase II poison. , 2002, Cancer research.